- Patent Title: Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
-
Application No.: US16731285Application Date: 2019-12-31
-
Publication No.: US11648307B2Publication Date: 2023-05-16
- Inventor: Kiyoshi Ariizumi , Ponciano Cruz
- Applicant: The Board of Regents of the University of Texas System
- Applicant Address: US TX Austin
- Assignee: The Board of Regents of The University of Texas System
- Current Assignee: The Board of Regents of The University of Texas System
- Current Assignee Address: US TX Austin
- Agency: Parker Highlander PLLC
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; C07K16/30 ; C12Q1/68 ; G01N33/574 ; C12Q1/6886 ; A61K45/06 ; A61K35/15 ; A61K39/00
Abstract:
The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.
Public/Granted literature
- US20200206343A1 ANTI-DC-HIL ANTIBODIES FOR CANCER DIAGNOSIS, PROGNOSIS AND THERAPY Public/Granted day:2020-07-02
Information query
